Background: The purpose of this study was to assess prognostic factors and outcome of patients with relapsed/ refractory Hodgkin's lymphoma (HL) who received high-dose chemotherapy and autologous stem-cell transplant (ASCT).
introduction High-dose chemotherapy and autologous bone marrow transplantation was first used in patients with Hodgkin's lymphoma (HL) almost 45 years ago but it has only in the last two decades become a standard in the treatment pathway for patients with relapsed or refractory disease [1] [2] [3] . With the use of peripheral blood stem cells, treatment-related morbidity and mortality are minimal and it offers another potential chance of cure for these patients who have relapsed after multiagent conventional chemotherapy. As prospective randomized studies have proved difficult to accrue to, current recommendations are on the basis of the reports of large series of prospectively collected data [1] [2] [3] .
Two prospective randomized analyses of HL patients autotransplanted in first relapse show a long-term progressionfree survival (PFS) advantage especially in those who have relapsed after a short first complete remission (CR) [2, 4] . A meta-analyses including >2000 patients confirm this [5] . There was no overall survival (OS) advantage but the studies were not powered to show this. BEAM conditioning with autologous bone marrow rescue was used. Data from single-center series and registry data show that about 40%-50% patients with relapsed HL who have received an autologous stem-cell transplant (ASCT) are alive after 5 years which is encouraging. However, at present there is no refined prognostic information for the individual patient at the time of ASCT that can be used to help them and their physician take an informed decision about the subsequent outcome.
The Hasenclever index is a proven guide in designing clinical trials for the treatment of advanced HL and making therapeutic decisions for newly diagnosed patients [6] . However, it has never been used to define outcomes when applied to pivotal moments in the treatment pathway (such as at the time of an ASCT) once treatment has started.
The Royal Marsden Hospital series is one of the world's largest single-center experience of elective single autografts in patients with relapsed/refractory HL patients with the longest follow-up and because of the mature nature of this data in terms of PFS and OS, we have used it as a model to see if Hasenclever index can define at the moment of ASCT, subgroups of patients that do better or worse. We have previously reported on 89 such patients; the data on these patients are included in the present paper [7] .
patients and methods
Prospectively gathered data on 195 consecutive HL who were autografted from 1985 to June 2005 at the Royal Marsden Hospital were analyzed. Follow-up on patients discharged from the Hospital was undertaken by ringing their general practitioners (GPs). Data on 199 patients were presented at American Society of Clinical Oncology 2005 meeting; on review of case notes, four patients received ASCT as consolidation postfirst-line therapy, hence they were excluded from this analyses [8] . The retrospective study was approved by the Local Regional ethics committee (Trial 2655; NCT00301314).
eligibility criteria
Patients £65 years of age (one patient in this group was >65, considered for ASCT in view of lower biological age and second relapse), left ventricular ejection fraction of >50%, glomerular filtration rate of >40 ml/min, forced expiratory volume in 1 s (FEV1) >50%, or transfer factor >75% predicted on lung function tests (see Table 1 ). Patients provided informed consent for the therapy.
definitions
Patients were staged according to the Ann Arbor system [9] . The prognostic criteria at the time of ASCT were assessed by the Hasenclever index [6] which incorporates seven prognostic factors: serum albumin level <4 g/dl, hemoglobin <10.5 g/dl, male sex, age ‡45 years, stage IV, leukocytosis ( ‡ 15 · 10 9 /l), and lymphocytopenia (<0.6 · 10 9 /l, <8% of white-cells, or both). Patients were divided into those with 0-2 or ‡3 factors.
Status at the time of ASCT was categorized as follows untested relapse-patients who did not receive salvage therapy at relapse and received an ASCT in relapse, chemosensitive-CR were patients with no evidence of disease clinically or radiologically, chemsensitive partial remission (PR) were patients with >50% reduction in size of tumor on computed tomography scan. Patients who did not fit any of these criteria were classified as resistant disease. Response was assessed by the International Union Against Cancer criteria [10] .
Patients received well-described regimens of treatment before the ASCT and included ABVD, Stanford V, HYBRID, ChlVPP, VEEP, MOPP/MVPP, LOPP/EVAP, and Hope-Bleo.
treatment plan
At relapse, treatment was variable, depending upon prior chemotherapy received (cumulative toxicity of bleomycin, adriamycin). All patients were treated with chemotherapy except six patients with untested relapses at the time of ASCT.
Before 1993, patients underwent bone marrow harvest from iliac crests under general anesthesia. From 1993, stem cells were mobilized with 12-16 lg/kg granulocyte colony-stimulating factor and collected by leukapheresis. This was done in those patients with no bone marrow involvement. The stem cells were cryopreserved without further manipulation. For conditioning, melphalan 180-220 mg/m 2 was used as a single agent in the first phase of the study. Carmustine (BCNU) 300-600 mg/m 2 was then added to melphalan 80-140 mg/m 2 as described previously [7] . Thereafter, the regimen MBE was used: melphalan 140 mg/m 2 , BCNU 300 mg/m 2 ( Table 2 shows patient characteristics at ASCT. These patients were heavily pretreated with median number of lines of treatment being 3 (2-7). In all, 117 (60%) patients received three or more lines of treatment before ASCT. A total of 57% had Hasenclever index ‡3 at ASCT. As shown, seven patients with lymphocyte predominant HL received an ASCT. Table 3 shows the treatment received before ASCT.
response and relapse Figure 1 shows the patient flow through treatment received. Post-ASCT, 119 of 195 (61%) patients attained CR, 46 PR, 4 patients had stable disease, 15 patients did not respond and 11 were not assessable for response as all of these patients died of transplant-related mortality (TRM). The overall response rate (CR + PR) was 85%. Of the 119 patients attaining CR, 27 relapsed, 3 of these relapsed at 5, 6, and 7 years post-ASCT, all these patients are alive after further salvage therapy; one patient relapsed after being in CR for 13 years 
deaths: early and late
In all, 93 patients have died-61 died of PD; 12 of TRM; 9 of interstitial pneumonitis related to high dose of BCNU used before 1990 (400-600 mg/m 2 ); 1 of renal failure; 1 of multiresistant pseudomonas sepsis; 1 from acute respiratory distress syndrome (combination chemotherapy with methotrexate, vinblastine and cisplatin); 9 died of second cancers (3 leukemia); 5 died as a result of a subsequent stem-cell transplant (4 matched unrelated donor, 1 autologous); 5 died in remission from suicide, progressive multifocal leukoencephalopathy (postmortem on brain biopsy), stroke, cryptococcal meningitis (postmortem), and pericarditis; cause of death remained unknown in 1 patient.
survival
A total of 102 patients are alive at median follow-up of 10.3 years (Figure 2 ). The median OS for the whole group was 9 years [95% confidence interval (CI) 1.9-16 years]. Five-year OS was 55% (95% CI 47.4% and 62.1%) and 10-year OS was 49.4% (95% CI 41% to 57%) for whole group. The median PFS from ASCT was 2.9 years (95% CI 1.1-4.7 years). Five-year PFS was 44% (95% CI 37% to 51%) and 10-year PFS was 37% (95% CI 29.5% to 44%) for the whole group.
conditioning
The 5-year OS for patients who received conditioning with MBE was 52% compared with 71% with ME and 45% with other regimens (P = 0.14); the 10-year OS being 50%, 57%, and 36% respectively. The 5-year PFS for patients who received conditioning with MBE was 47% compared with 37% with ME and 41% with other regimens (P = 0.4); the 10-year PFS being 40%, 20%, and 36% respectively. The 5-year OS for patients who received bone marrow as source of stem cells was 51% compared with 62% for those who received peripheral blood stem cells (P = 0.14). The 5-year PFS for patients who received BM was 45% compared with 43% with PBSC (P = 0.11)
chemosensitivity
The 5-year OS for patients who were in CR at the time of ASCT was 79% compared with 59% for those in PR and 17% for those with resistant disease at the time of ASCT (P < 0.0001); the 10-year OS being 72%, 54%, and 11%, respectively (Figure 3a and b) . The 5-year PFS for patients who were in CR at the time of ASCT was 69% compared with 44% for those in PR and 14% for those with resistant disease at the time of ASCT (P < 0.0001); the 10-year PFS being 59%, 37%, and 7% respectively.
Hasenclever index
The 5-year OS for patients with a Hasenclever index of zero to two was 71% compared with 41.5% for those with three or more prognostic factors [hazards ratio (HR) 2.29; 95% CI 1.53-3.44; P = 0.0001]; the 10-year OS being 67% and 34%, respectively (Figure 4a and b) . The 5-year PFS for patients with a Hasenclever index of zero to two was 60% compared with 32% for those with three or more prognostic factors (HR 1.93; 95% CI 1.38-2.7; P = 0.0001); the 10-year PFS being 53% and 23%, respectively.
second malignancies
Twenty patients (10%) developed second cancers at a median of 5.8 years (0.2-19 years) post-ASCT. Of these, seven patients developed acute myeloid leukemia or secondary myelodysplastic syndrome (five did not receive prior radiotherapy (RT)); two developed transitional carcinoma of bladder (no prior RT); three basal cell cancer (all had previously received mantle RT); one metastatic gastric cancer (no RT), one metastatic colon cancer (RT pre-ASCT), two metastatic breast cancer (both received mantle RT), one mesothelioma (mantle RT), one diffuse large B-cell lymphoma (received previous RT), one lung cancer (no RT), and one carcinoma of tongue (no RT).
Probability of developing second cancer at 10 years is 14.7% (95% CI 8.9% to 23.8%) and 24.8% at 19 years. There is no significant difference in probability of developing a solid tumor and secondary AML/MDS (P = 0.17), though the risk of developing a solid tumor increases with longer follow-up. Ten-year probability of developing AML/MDS is 7% compared with 8% for solid tumor; 15-year probability of developing AML/MDS is 7% compared with 19% for solid tumors.
Cox analysis
As Table 4 shows, Hasenclever index and chemosensitivity at the time of ASCT are the only two factors predicting both OS and PFS in this group of patients.
discussion
The 195 patients in this paper who received an ASCT as treatment for relapsed/refractory HL between 1985 and 2005 represent the longest reported follow-up from a single center and are the basis of determining the risk of late relapse and prognostic criteria relevant to long-term follow-up.
In this study, we showed the 10-year OS/PFS of the whole group of 195 patients was 50% of 37% which is comparable to various other published studies as shown in Table 5 , [18, 19] . The outcome of this group of patients (5-year and 10-year follow-up data) is better or similar to that reported for a similar group of patients not receiving an autotransplant [20] . 
Annals of Oncology original article
The outcome was extremely favorable for the 54 patients who were already in CR at the time of ASCT. These findings have been reported in several recently published trials. The Polish Lymphoma Research Group study identified in their multivariate analysis that CR or PR before ASCT was an independent prognostic factor for the 5-year OS (CR: 77% and PR 71%, <PR: 33%; P < 0.001) [17] . Similar results have been reported by the Spanish Lymphoma Group [21] . Another single-institution trial could confirm these findings in the univariate analysis and reported that patients who underwent ASCT in CR had less TRM compared with patients with active disease. However, CR status did not reach significance in the multivariate analysis as a prognostic factor for OS in this study [22] . Our study provides further evidence of the efficacy of ASCT in patents with HL and supports the use of intensive debulking before mobilization of PBSC to maximize therapeutic benefit. The intensive regimen bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisolone (BEACOPP) has been proposed as an effective induction for patients with high-risk HL [23] . A randomized trial of ABVD compared with BEACOPP, both coupled with an ASCT salvage program in patients who do not respond to induction therapy, is underway in Italy.
The results from our study also show that in patients who have had more than two lines of treatment, it is possible to treat patients with multiple recurrences and attain disease control. There was no difference in PFS or OS according to the source of stem cells infused in our study (P = NS). These findings were in accordance with other studies [17, 22] .
However, the key to this paper has been our use of the Hasenclever index done at the time of ASCT. This is usually used at diagnosis and has become a standard prognostic test. It has also been used at the time of relapse with some reproducibility but we decided to see if we could use it at the time of ASCT which would of course be at a point when some patients had just completed treatment and were in CR. With measures such as lymphocyte count, this might reflect an effect of treatment rather than disease, but if this staging was going to be useful in the future for determining what the prognosis was for an individual patient, if it could be done just before the ASCT, when the balanced decision was required about the usefulness of such a procedure at that moment in time for that particular patient. We found that the Hasenclever index was a strong indicator of outcome and may be considered at the time of ASCT to predict outcome.
Concerning the TRM of this procedure in our patients, the overall mortality for the whole series was 6% but with the original article Annals of Oncology optimization of the conditioning regimens (BCNU dose reduction and consideration of previous mantle radiotherapy), the use of PBSCs rather than bone marrow as the source of stem cells, the mortality has declined and currently <1%. This is in accordance with previously reported studies from same time-period. Polish Lymphoma Research Group analyzed the outcome of 341 advanced HL patients who underwent ASCT from April 1990 to March 2002 and found a TRM of 5% [17] . Spanish Lymphoma Group reported a TRM of 9% in a group of 494 refractory/relapsed HL patients who underwent a similar approach from January 1984 to May 1998 [21] . A TRM of 13% has been demonstrated [24] . The higher TRM of the latter trial was a result of the use of total body irradiation (TBI) or the use of high-dose BCNU which has been part of the standard conditioning regimens in the earlier days of ASCT. These findings have been confirmed in a smaller Spanish study where TBI was a significant negative prognostic factor for overall TRM (36% versus 9%) [22] . Concerning long-term toxicity, we did not formally assess long-term survivors in this study for quality of life and other toxicity measures but this may be the basis of a later study. However, we did ask GPs to give us from their records information concerning second cancers, the results indicated that even with longer follow-up than other reported studies, the time corrected incidence of cancer is the same as described by others in nontransplant population [25] . Of the seven patients who developed AML (five never received prior RT), three had received prior ChlVPP, two MOPP/MVPP, one Stanford V, one CHOP + procarbazine-bleomycin. As shown by Bonadonna et al. [25] , the risk of developing leukemia/MDS is most in the first decade from starting chemotherapy, while the risk for all solid cancers started to increase after the ninth year. Risk of AML was more with MOPP-like regimens (cumulative risk of 6%) and the risk of solid tumors more so with primary ABVD regimens (22% cumulative risk). The two patients with breast carcinoma had both previously received mantle RT which has been shown to be risk factor [26] . Risk is quite likely related to the previous chemotherapy received rather than the ASCT itself as shown by Harrison et al. [27] that there is no evidence of a significantly increased risk of MDS/AML with BEAM and ASCT.
Long-term follow-up in this group of patients is a median of 10 years. We are able to define the risk of late relapse. As shown, late relapses were seen even after the patients have been in CR for up to 5 years; one patient relapsed after being in CR for >10 years which is previously not described in this disease. This is considered typical of patients with lymphocyte predominant HL [28] but this patient had nodular sclerosing HL. This study provides long-term follow-up evidence of the safety of ASCT in patients with HL and also is sufficiently encouraging in a nonrandomized comparison with published data to suggest that it should be now formally evaluated. This is currently being undertaken in the CORAL and Italian study and it maybe that these studies can test our prognostic criteria using the Hasenclever index to determine whether this is useful in a randomized setting. 
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